Drug Profile

O-desulfated heparin inhalation - ParinGenix

Alternative Names: PGX-200

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ParinGenix
Class Anti-inflammatories; Antiasthmatics; Blood proteins; Heparins; Ischaemic heart disorder therapies
Mechanism of Action Cathepsin G inhibitors; Leucocyte elastase inhibitors; P selectin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cystic fibrosis
New Molecular Entity Yes

Highest Development Phases

No development reported Acute asthma; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

30 Mar 2005 Preclinical trials in Acute asthma in USA (Inhalation)
30 Mar 2005 Preclinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
30 Mar 2005 Preclinical trials in Cystic fibrosis in USA (Inhalation)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com